Managers’ meeting next week

Discussion in 'Ironwood Pharmaceuticals' started by anonymous, Jun 5, 2018 at 9:58 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Round 2?
     

  2. anonymous

    anonymous Guest

    Yes, there are preparations ongoing for round 2 and these meetings are part of it. Protect yourself and make the moves to leave.
     
  3. anonymous

    anonymous Guest

    FAKE NEWS
     
  4. anonymous

    anonymous Guest

    Management was called to meeting to prepare to sell against new Trulance data presented at DDW this week. Doesn’t look good for Linzess, data shows Trulance is superior and Linzess harms patients. Good luck everyone.
     
  5. anonymous

    anonymous Guest

    The more I read the data released at the DDW conference - a composite of 5 phase 3 trials showing both harm and benefit between Linzess is in serious trouble, despite tremendous advantages in resources.
    However, Linzess is in deep guana, and the sand will henceforth be shifting under their feet. Synergy will have easy path to take over a tremendous market, while developing a possible game changer with Dolcanotide-Linzess CR won’t even have a chance!
     
  6. anonymous

    anonymous Guest

    Thank you Synergy reps! Your posts aren’t convincing just like the data for your drug.
     
  7. anonymous

    anonymous Guest

  8. anonymous

    anonymous Guest

    That’s why you dive off on disability! Lol
     
  9. anonymous

    anonymous Guest

    Hey Everyone,
    What do you think is going to happen here? Trying not to listen to the rumors but everyone is speculating. What is Ironwood's future?
     
  10. anonymous

    anonymous Guest

    I don’t see how it can be anything but a buyout.
     
  11. anonymous

    anonymous Guest

    A buyout is wishful thinking. Linzess probably won't clear $1B in U.S. Annual Sales (remember IRWD gets less than half that), plus competitor Trulance is having horrible drug launch..proving that the CIC RX space isn't as large as IRWD execs thought it was. Linzess CR is a play for patent extension, there's really no benefit to that product, and the gout drugs should just be sold to a generic company already. The GERD drug remains doubtful, pill size is way too large for patients and TID dosing isn't so attractive.